A. MENARINI FARMACEUTICA INTERNAZIONALE SRL

What A. MENARINI FARMACEUTICA INTERNAZIONALE SRL does

A. Menarini Farmaceutica Internazionale SRL is the UK subsidiary of the Menarini Group, Italy's largest pharmaceutical company, which is headquartered in Florence and family-owned since its founding in 1886. The UK entity operates as a registered branch (BR016024) based in High Wycombe, Buckinghamshire, employing over 50 staff dedicated to commercial operations across the United Kingdom. It markets branded prescription pharmaceutical products to NHS and private healthcare providers through a dedicated field sales force engaging prescribers in hospitals, primary care, and specialist settings.

The UK portfolio spans cardiology (RANEXA/ranolazine), diabetes and endocrinology (INVOKANA/canagliflozin), anti-infectives with an explicit antimicrobial resistance focus, men's health, and the dermatology and aesthetic franchise RELIFE. Products are dispensed through pharmacies and supplied through traditional pharmaceutical distribution channels. Pricing is not publicly disclosed, and revenue is derived from one-time product sales under prescription frameworks. The company maintains GDPR-compliant data processing, publishes adverse-event reporting channels, and operates under the ABPI code of practice.

Beyond product commercialization, the UK subsidiary engages in NHS collaborative working projects under the ABPI Collaborative Working framework, with a medical affairs function available for partnership enquiries. The entity is supported by the parent group's multinational infrastructure, including in-house manufacturing, regulatory affairs, and supply across 140 countries, enabling consistent product availability and quality standards in the UK market.

Name

A. MENARINI FARMACEUTICA INTERNAZIONALE SRL

Legal name

A. Menarini Farmaceutica Internazionale SRL

Website

https://menarini.co.uk

Company type

Private

Founded year

1886

Operating status

Operating

Headcount range

11–50 employees

Short description

UK subsidiary of Italy's Menarini Group (Florence-headquartered family-owned pharma founded 1886), marketing branded prescription drugs in cardiology, diabetes, anti-infectives, men's health, and dermatology/aesthetics to NHS and UK healthcare professionals via a field sales force.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Prescription pharmaceuticals
• Cardiology medications
• Diabetes treatments
• Anti-infective drugs
• Dermatology aesthetics

Headquarters

HQ city

High Wycombe

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical product sales: Revenue generated from sale of prescription pharmaceutical products including cardiovascular medications (RANEXA/ranolazine), diabetes treatments (INVOKANA/canagliflozin), anti-infectives, and specialty pharmaceuticals across therapeutic areas.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

A. Menarini Farmaceutica Internazionale SRL markets and distributes a portfolio of branded prescription pharmaceutical products in the UK across cardiology, diabetes and endocrinology, anti-infectives, men's health, and dermatology/aesthetics (RELIFE). Products such as RANEXA (ranolazine) for cardiology and INVOKANA (canagliflozin) for diabetes are sold to NHS hospitals, primary care organisations, and healthcare professionals through dedicated field sales teams, with collaborative working partnerships via the ABPI framework.

Product overview

A. Menarini Farmaceutica Internazionale SRL is the UK subsidiary of the Menarini Group, Italy's largest pharmaceutical company headquartered in Florence. The company operates as a pharmaceutical manufacturer and marketer, offering a portfolio of branded pharmaceutical products across multiple therapeutic areas. In the UK market, Menarini has established itself in cardiology (with products such as RANEXA), anti-infectives, and men's health, and has recently launched a dermatology and aesthetic franchise under the RELIFE sub-brand. The product portfolio includes INVOKANA (canagliflozin) for diabetes and endocrinology, and RANEXA (ranolazine) for cardiology. The company also focuses on collaborative working projects with healthcare organisations and the NHS, while maintaining commitments to business ethics, data privacy compliance (GDPR), and quality standards.

Differentiator

Problem solved

Functional benefit

Brands

• Relife: Dermatology and aesthetic franchise launched by Menarini UK.

Products and services

• RANEXA (ranolazine) RANEXA (ranolazine) is a branded prescription pharmaceutical product used in the treatment of cardiology conditions, indicated for the treatment of cardiovascular conditions such as angina. It is marketed to NHS hospitals, primary care organisations, and prescribers in the UK.
• INVOKANA (canagliflozin) INVOKANA (canagliflozin) is a branded prescription pharmaceutical product indicated for the treatment of diabetes and endocrinology conditions. It is marketed to NHS hospitals, primary care organisations, and prescribers in the UK as part of the diabetes franchise.
• RELIFE (dermatology and aesthetics franchise) RELIFE is a dermatology and aesthetic medicine franchise launched by Menarini UK, offering products for dermatological conditions and aesthetic medicine. It operates as a wholly-owned sub-brand of A. Menarini Farmaceutica Internazionale SRL.

Named customers1 record

Segments6 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• NHS (National Health Service)coreStrategic or Co-development PartnerMenarini UK is committed to working in partnership with the NHS through the ABPI Collaborative Working framework. The company implements sustainable healthcare projects which benefit patient outcomes and NHS system efficiencies. As a family-owned company, Menarini takes a long-term view and works together with healthcare organisations to improve population health. The company publishes summaries of collaborative working projects before commencement and shares outcomes to enable learning.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UC164BrJajSmI2iwxe_Ybnyg
• Facebookfacebook.com/FairPlayMenariniInternationalAward
• Instagraminstagram.com/fairplaymenarini/?igshid=YmMyMTA2M2Y=
• LinkedInlinkedin.com/company/a.-menarini-farmaceutica-internazionale-srl

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about A. MENARINI FARMACEUTICA INTERNAZIONALE SRL